- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Eli Lilly moves to settle with whistleblower who flagged alleged manufacturing shortfalls | ||
| Fr | In label expansion bid, AbbVie and Roche's Venclexta falls short in multiple myeloma subset | ||
| Fr | Teva continues its transformation, hiring Christine Fox to take over US business | ||
| Fr | Proposed chemical ban would cause EU drug manufacturing to 'grind to a halt,' trade group warns | ||
| Fr | AstraZeneca hit by 6 Symbicort marketing rule breaches, with patient safety concerns leading the most serious violation | ||
| Fr | As Novo Nordisk boosts Wegovy, Ozempic ad spend, analysis finds 'a rising tide lifts all boats' for diabetes, weight-loss drugs | ||
| Do | After Amicus scores FDA nod for Pompe disease combo, it's game on with Sanofi | ||
| Do | CureVac touts 'progress' as German court suspends infringement proceedings against BioNTech | ||
| Do | In second attempt, Takeda scores FDA nod for subcutaneous version of Entyvio | ||
| Do | J&J's Rybrevant combo bests AstraZeneca's established Tagrisso in key lung cancer study | ||
| Do | Novo Nordisk's Ozempic gets FDA label update flagging risk of intestinal blockage disorder | ||
| Do | As it ramps up marketing for Zoryve and preps for a new approval, Arcutis nabs new chief commercial officer from Incyte | ||
| Do | Bluebird taps Lonza to boost manufacturing capacity for its gene therapies Zynteglo, Skysona | ||
| Do | GSK dials up HIV sales projection to £7B by 2026, updates next-gen launch timelines | ||
| Do | Survey finds 80% of HCPs mistrust pharma's digital content, with data cherry picking a top concern | ||
| Mi | 'We can't forget about this': As chemotherapy shortage ebbs and flows, attention shifts to long-term solutions | ||
| Mi | Will Big Pharma commit to engage in CMS price negotiations? The verdict's not in | ||
| Mi | As Viatris seeks growth in eye care, its Ocuphire-partnered dilation drop Ryzumvi wins FDA nod | ||
| Mi | In Emgality patent case against Teva, Lilly wins reversal of $177M verdict | ||
| Mi | NICE poised to reject AstraZeneca, Daiichi's Enhertu in HER2-low breast cancer | ||
| Mi | Hermes Pharma earmarks €25M to expand oral drug production capacity | ||
| Mi | UK watchdog blasts Croma for launching Botox rival at 5-star Monte Carlo hotel | ||
| Di | WuXi debuts first vaccine CDMO site in China, where it plans to employ more than 500 | ||
| Di | Merck KGaA's MilliporeSigma pumps €28M into 2 new mRNA production plants | ||
| Di | After two FDA rejections and restructuring drive, Intercept sells itself to Italy's Alfasigma |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
